Beijing, China:
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) introduced the firm’s official itemizing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, businesses, collaborative companions, and worker representatives attended the itemizing ceremony. In whole, 21.76 million shares had been provided globally with a value of HK$ 25.22 per share. The internet proceeds from the Global Offering might be roughly HK$ 471.1 million.
This press launch options multimedia. View the full launch right here: https://www.businesswire.com/news/home/20220831005904/en/
Biocytogen’s itemizing ceremony (Photo: Business Wire)
Since its institution in 2009, Biocytogen has established a sequence of genetically modified animal and cell fashions utilizing superior proprietary applied sciences, together with goal humanized mice and severely immunodeficient mice. The firm harnesses these specialised fashions to present preclinical pharmacology analysis providers for world pharmaceutical/biotech corporations. These services drastically speed up the analysis and growth of novel medication.
Biocytogen’s proprietary size-unlimited, exact chromosome engineering (SUPCE) know-how, which was developed over a interval of 6 years, was utilized to generate a sequence of absolutely human antibody mice (RenMiceTM), together with RenMabTM and RenLite®. The firm has developed 5 core antibody growth platforms utilizing RenMiceTM, together with a totally human monoclonal antibody discovery platform, bispecific antibody discovery platform, bispecific ADC platform, GPCR antibody platform and TCR-mimic antibody platform, which type the core competitiveness of Biocytogen’s antibody drug discovery functionality. The firm’s RenMiceTM-based “Project Integrum”, a large-scale antibody discovery and growth program launched in 2020, includes deriving knockout RenMiceTM, goal verification and antibody discovery for 1000+ potential antibody-druggable targets. With these 5 antibody platforms, Biocytogen plans to repeatedly produce novel antibody drug molecules that may be licensed or co-developed with world pharmaceutical/biotech corporations. Over the previous two years, the firm has generated 1000+ goal gene knock-out RenMiceTM, with 300+ targets present process antibody screening, 240+ targets with hits molecules recognized, and PCCs obtained for practically 20 targets. Biocytogen strives to turn out to be the headstream of novel antibody medication.
With gene-edited animal and cell fashions serving as the basis, Biocytogen has developed an progressive evidence-based in vivo drug efficacy and security screening course of. These preclinical discovery and pharmacology platforms have supported the institution of 10+ preclinical and medical pipelines, together with monoclonal antibodies, bispecific antibodies and bispecific ADCs; 3 merchandise have been out-licensed and/or entered co-development. The firm’s main merchandise, YH003 (CD40 mAb) and YH001 (CTLA-4 mAb), are presently in section II multi-regional medical trials and world drug growth, with their section I research exhibiting wonderful security profiles and promising preliminary anti-tumor actions.
Biocytogen has developed over 2500 progressive animal fashions since 2013 and these fashions have been bought to greater than 20 nations round the world. In the future, 1000+ progressive fashions are anticipated to be efficiently developed and put into the market. Biocytogen has accomplished greater than 500 preclinical antibody drug analysis tasks for greater than 200 biopharmaceutical corporations, together with many of the high 10 world biopharmaceutical corporations. The firm has licensed the RenMiceTM platform to 14 corporations, together with Merck Healthcare KGaA, BeiGene, Xencor and Innovent; 32 tasks have initiated. Additionally, the firm has reached 24 preclinical antibody co-development or license agreements with 15 corporations, together with Merck Healthcare KGaA, RemeGen, China Resources Biopharm, Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) and LiberoThera. The firm can be collaborating with companions comparable to Remgen, TRACON and Gene Quantum to co-develop preclinical and medical antibody drug pipelines.
When picturing the future of Biocytogen, Dr. Yuelei Shen, Founder, Chairman and CEO, stated: “Biocytogen’s fast growth and development is impossible without the efforts of all employees, the strong support of local government, shareholders, and global collaborators. Listing on the Hong Kong Stock Exchange is the recognition of our company’s past achievements and the trust for our company’s future growth from the capital market. We believe that with the help of the HKEX listing, Biocytogen will further strengthen innovative research and development, continue to produce high-quality products and services, and persist in flexible and mutually beneficial business collaboration models. As a biotechnology company rooted in China with a global view, we strive to further accelerate the globalization of the company’s business and give back to our shareholders, employees, and society with excellent achievements and financial return.”
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a world biotechnology firm that drives the analysis and growth of novel antibody-based medication with progressive applied sciences. Using its proprietary RenMabTM /RenLite® mice platforms for absolutely human monoclonal and bispecific antibody growth, Biocytogen has built-in its in vivo drug efficacy screening platforms and robust medical growth experience to streamline the complete drug growth course of. Biocytogen is endeavor a large-scale mission to develop antibody medication for greater than 1000 targets, often known as Project Integrum, and has entered ongoing collaborations with dozens of companions worldwide to produce a spread of antibody medication. The firm’s pipeline contains 12 core merchandise, amongst which two merchandise are in section II multi-regional medical trials and two merchandise are in section I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For extra info, please go to www.biocytogen.com.cn.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220831005904/en/
